Disease-modifying antirheumatic drugs (DMARDs), including methotrexate, sulfasalazine, azathioprine, and anti-TNF-α agents, were prescribed to 4 patients (33.3%) due to ongoing inflammation characterized by osteitis and colitis. This evidence concerns the gene TNF and bone inflammation disease.